| 日期 | 主要股東
| 每股
平均價 | 類型 | 買/賣或涉及
股份數目 | 變動股數
佔已發行股(%) | 目前持股量 | 佔已
發行股(%) |
| 2025-06-27 | 盧安邦 | | 1102 (L) | 435,000(L) | N/A | 5435000(L) | 4.77(L) |
| 2025-04-24 | 盧安邦 | | N/A
1312 (S) | N/A
1,707,700(S) | N/A
N/A | 5000000(L)
N/A | 4.39(L)
N/A |
| 2025-03-21 | 盧安邦 | | 1701 (L)
1313 (S) | 5,000,000(L)
1,707,700(S) | N/A
N/A | 5000000(L)
1707700(S) | 4.39(L)
1.49(S) |
| 2025-03-21 | Vivo Capital IX (Cayman), LLC | | 1711 (L) | 37,167,064(L) | N/A | 37167064(L) | 32.62(L) |
| 2025-03-21 | Vivo Capital Fund IX(Cayman), L.P. | | 1711 (L) | 37,167,064(L) | N/A | 37167064(L) | 32.62(L) |
| 2025-03-21 | Vivo Plenilune IX Limited | | 1711 (L) | 37,167,064(L) | N/A | 37167064(L) | 32.62(L) |
| 2025-03-21 | Ascendis Pharma A/S | | 1701 (L) | N/A | N/A | 41136364(L) | 36.11(L) |
| 2025-03-21 | Ascendis Pharma Bone Diseases A-S | | 1701 (L) | N/A | N/A | 12855114(L) | 11.28(L) |
| 2025-03-21 | Ascendis Pharma Growth Disorders A-S | | 1701 (L) | N/A | N/A | 7713068(L) | 6.77(L) |
| 2025-03-21 | Ascendis Pharma Endocrinology Division A-S | | 1701 (L) | N/A | N/A | 20568182(L) | 18.05(L) |
| 2025-03-21 | Vivo Plenilune IX Limited | | 1001 (L) | 36,136,364(L) | N/A | 36136364(L) | 32.14(L) |
| 2025-03-21 | Vivo Capital Fund IX(Cayman), L.P. | | 1001 (L) | 36,136,364(L) | N/A | 36136364(L) | 32.14(L) |
| 2025-03-21 | Vivo Capital IX (Cayman), LLC | | 1001 (L) | 36,136,364(L) | N/A | 36136364(L) | 32.14(L) |